Ram Palanki
Director/Board Member bei EYENOVIA, INC.
Vermögen: 36 904 $ am 31.03.2024
Profil
Ram Palanki is the founder of Revopsis Therapeutics, Inc. (founded in 2018) where he holds the title of Director.
He is currently the Chairman at AAVantgarde Bio Srl, Independent Director at Eyenovia, Inc., and Executive VP-Commercial Strategy & Operations at REGENXBIO, Inc. Dr. Palanki has previously worked as the Director-Global Marketing & Sales at NeoVista, Inc. from 2008 to 2010, Principal at Rutgers State University of New Jersey, Principal at Novartis Pharmaceuticals Corp.
from 2001 to 2003, Head-Marketing at Oxurion NV, Senior Vice President-Commercial at Santen, Inc., and Head-Global Marketing & Sales at Thrombogenics, Inc. from 2010 to 2013.
He has a doctorate degree from Albany College of Pharmacy & Health Sciences (conferred in 2001) and a graduate degree from Rutgers State University of New Jersey.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
EYENOVIA, INC.
0,08% | 27.06.2023 | 37 428 ( 0,08% ) | 36 904 $ | 31.03.2024 |
Aktive Positionen von Ram Palanki
| Unternehmen | Position | Beginn |
|---|---|---|
| REGENXBIO INC. | Corporate Officer/Principal | - |
| EYENOVIA, INC. | Director/Board Member | 01.07.2022 |
AAVantgarde Bio Srl
 AAVantgarde Bio Srl Miscellaneous Commercial ServicesCommercial Services AAVantgarde Bio Srl is a clinical stage biotechnology start-up based in Milan, Italy. The Italian company has developed proprietary adeno-associated viral (AAV) vector platforms that allow for the delivery of large genes for inherited retinal disorders. Co-founded by Professor Alberto Auricchio and originating from the research activities carried out at TIGEM (Telethon Institute of Genetics and Medicine), AAVantgarde's platforms are focused on broadening the application of AAV-based therapies by addressing the limitations of single AAV therapies cargo capacity. Natalia Misciattelli has been the CEO of the company since 2022. | Chairman | 31.03.2022 |
Revopsis Therapeutics, Inc.
 Revopsis Therapeutics, Inc. BiotechnologyHealth Technology Revopsis Therapeutics, Inc. is a company based in Dover, DE. Ramanath Bhandari has been the CEOs since incorporation. Revopsis Therapeutics, Inc. was founded by Ram Palanki, Ramanath Bhandari, Jeff Olson. | Founder | 01.01.2018 |
Ehemalige bekannte Positionen von Ram Palanki
| Unternehmen | Position | Ende |
|---|---|---|
Thrombogenics, Inc.
 Thrombogenics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Oxurion NV, Thrombogenics, Inc. operates as a biotechnology company that delivers innovative treatments for diseases of the back of the eye, with a focus on diabetic eye disease. The private company is based in New York, NY. | Sales & Marketing | 01.12.2013 |
NeoVista, Inc.
 NeoVista, Inc. Medical SpecialtiesHealth Technology NeoVista, Inc. develops device-based therapy for age-related macular degeneration (AMD). The firm's technology utilizes targeted strontium 90 beta radiation in a one-time surgical procedure and this technology has the possibility to reduce the burden that wet AMD places on healthcare providers, patients, and the healthcare system. The company was founded in 2002 and is headquartered in Newark, CA. | Sales & Marketing | 01.10.2010 |
Novartis Pharmaceuticals Corp.
 Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Corporate Officer/Principal | 01.01.2003 |
Santen, Inc.
 Santen, Inc. Medical SpecialtiesHealth Technology Part of Santen Pharmaceutical Co., Ltd., Santen, Inc. is a private company that develops ophthalmic products. The company is based in Emeryville, CA. The company was founded in 1993 by Adrienne L. Graves. Tatsuya Kaihara has been the CEO of the company since 2017. | Corporate Officer/Principal | - |
| OXURION NV | Sales & Marketing | - |
Ausbildung von Ram Palanki
| Albany College of Pharmacy & Health Sciences | Doctorate Degree |
| Rutgers State University of New Jersey | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 3 |
|---|---|
| REGENXBIO INC. | Health Technology |
| OXURION NV | Health Technology |
| EYENOVIA, INC. | Health Technology |
| Private Unternehmen | 6 |
|---|---|
NeoVista, Inc.
NeoVista, Inc. Medical SpecialtiesHealth Technology NeoVista, Inc. develops device-based therapy for age-related macular degeneration (AMD). The firm's technology utilizes targeted strontium 90 beta radiation in a one-time surgical procedure and this technology has the possibility to reduce the burden that wet AMD places on healthcare providers, patients, and the healthcare system. The company was founded in 2002 and is headquartered in Newark, CA. | Health Technology |
Novartis Pharmaceuticals Corp.
Novartis Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Corp. develops, manufactures, and markets prescription drugs. It manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular, dermatological, central nervous system, bone disease, cancer, organ transplantation, psychiatry, infectious disease, and respiratory. The company was founded in 1996 and is headquartered in East Hanover, NJ. | Health Technology |
Santen, Inc.
Santen, Inc. Medical SpecialtiesHealth Technology Part of Santen Pharmaceutical Co., Ltd., Santen, Inc. is a private company that develops ophthalmic products. The company is based in Emeryville, CA. The company was founded in 1993 by Adrienne L. Graves. Tatsuya Kaihara has been the CEO of the company since 2017. | Health Technology |
AAVantgarde Bio Srl
AAVantgarde Bio Srl Miscellaneous Commercial ServicesCommercial Services AAVantgarde Bio Srl is a clinical stage biotechnology start-up based in Milan, Italy. The Italian company has developed proprietary adeno-associated viral (AAV) vector platforms that allow for the delivery of large genes for inherited retinal disorders. Co-founded by Professor Alberto Auricchio and originating from the research activities carried out at TIGEM (Telethon Institute of Genetics and Medicine), AAVantgarde's platforms are focused on broadening the application of AAV-based therapies by addressing the limitations of single AAV therapies cargo capacity. Natalia Misciattelli has been the CEO of the company since 2022. | Commercial Services |
Revopsis Therapeutics, Inc.
Revopsis Therapeutics, Inc. BiotechnologyHealth Technology Revopsis Therapeutics, Inc. is a company based in Dover, DE. Ramanath Bhandari has been the CEOs since incorporation. Revopsis Therapeutics, Inc. was founded by Ram Palanki, Ramanath Bhandari, Jeff Olson. | Health Technology |
Thrombogenics, Inc.
Thrombogenics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Oxurion NV, Thrombogenics, Inc. operates as a biotechnology company that delivers innovative treatments for diseases of the back of the eye, with a focus on diabetic eye disease. The private company is based in New York, NY. | Commercial Services |
